A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
"You need to understand that we're about to embark on the busiest week of the year for industrial earnings," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Boston Federal Reserve President Eric Rosengren is lining up against an apparent push to cut interest rates, telling CNBC in an interview Friday that the central bank can...The Fedread more
The MTA reported that the 1, 2, 3, 4, 5 and 6 trains are all facing delays due to a network communications issue impacting service in both directions, NBC New York reports.Transportationread more
Companies aren't waiting for the U.S.-China trade war to be resolved, says the head of the world's biggest money manager.Investingread more
US officials including Treasury Secretary Steven Mnuchin and White House economic adviser Larry Kudlow will host a meeting at the White House on Monday of semiconductor and...Technologyread more
Trump's constant berating of the Fed and its actions does not influence the central bank's decisions, Boston Fed's Eric Rosengren says.The Fedread more
The lawsuits allege J&J's talc-based baby powder contained asbestos and caused ovarian and other cancers.Health and Scienceread more
Biotech investors breathed easier Monday, at least for a few moments, after last week's beating.
The Nasdaq Biotech Index opened positively Monday, before leveling off midday, as many of the larger names—Biogen Idec, Celgene, Gilead Sciences—recovered from dips and companies including Lexicon Pharmaceuticals turned in positive clinical trial data.
Lexicon, based in The Woodlands, Texas, was among the leaders in the Nasdaq Biotech Index, jumping as much as 5.7 percent after its experimental medicine for diabetes met the goals of a mid-stage clinical study. The drug, LX4211, reduced mealtime insulin use and improved glycemic control for people with Type 1 diabetes, Lexicon said Monday in a statement. The company also is testing the medicine in Type 2 diabetes, the more common of the two forms, and has been seeking a partner to help fund larger, later-stage studies, according to Phil Nadeau, an analyst with Cowen & Co.
Akebia Therapeutics, a Cambridge, Mass.-based drugmaker that went public in March, also gained after analysts initiated coverage of the stock with price targets as high as $90. The shares closed Friday at $16.86.
Akebia is developing a medicine called AKB-6548 for anemia due to chronic kidney disease, what Nomura analyst M. Ian Somaiya calls a $6 billion global market opportunity. Somaiya initiated coverage Monday with a "buy" rating and price target of $39, while Credit Suisse's Ravi Mehrotra pegged his target at $25, with an "outperform" rating. Morgan Stanley's David Friedman set a $90 price target, noting he sees more than $2 billion in worldwide sales potential in the drug's first indications.Clinical trial data are expected in the fourth quarter.
Even companies with negative news participated in the gains. Acorda Therapeutics rose 4.6 percent despite news Monday that a study of its drug for stroke would be delayed. The stock had been upgraded at FBR Capital Markets to "outperform."
The larger-cap companies, too, initially rallied, with Biogen regaining more than 3 percent, and Celgene and Gilead more than 2 percent. The EASL (European Association for the Study of the Liver) conference wrapped in London over the weekend, and despite strong data from Merck, AbbVie and others, Gilead remains the hepatitis C darling.
"Gilead's data remains impressive and the simplicity of their regimen will enable it to be the dominant player in the space," Credit Suisse's Mehrotra wrote Sunday in a note.
Nomura's Somaiya points out Gilead is trading at a discount to the S&P, suggesting "current levels represent an even more compelling buying opportunity."
—By CNBC's Meg Tirrell.
(UPDATE: This story was updated from the original to reflect the movement in the stocks as well as to provide additional information about analysts' price targets for Akebia.)